STAAR Surgical Publishes Q3 2026 Earnings Call Transcript

• STAAR Surgical's November 4 third-quarter 2026 earnings call featured CEO Warren Foust and CFO Deborah J. Andrews.
• Net sales rose 21% to $83.4 million, excluding deferred China sales recognized a year earlier.
• China sales grew 31% on the same basis, entirely from higher-priced product mix; lens demand exceeded available supply.
• Management expects fourth-quarter gross margin above 70.9%, with further improvement in 2027 as manufacturing unit costs decline.
• Two presbyopia lenses are expected to enter first-in-human trials within months, subject to regulatory authorization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. STAAR Surgical Company published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.